TLIS vs. ASTC, BNGO, PRPO, STAI, TBIO, SMIT, SPEC, HTGMQ, OLITW, and PRENW
Should you be buying Talis Biomedical stock or one of its competitors? The main competitors of Talis Biomedical include Astrotech (ASTC), Bionano Genomics (BNGO), Precipio (PRPO), Scantech AI Systems (STAI), Telesis Bio (TBIO), Schmitt Industries (SMIT), Spectaire (SPEC), HTG Molecular Diagnostics (HTGMQ), OmniLit Acquisition (OLITW), and Prenetics Global (PRENW). These companies are all part of the "measuring and control equipment" industry.
Talis Biomedical vs.
Astrotech (NASDAQ:ASTC) and Talis Biomedical (NASDAQ:TLIS) are both small-cap aerospace companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation.
Astrotech has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Comparatively, Talis Biomedical has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.
Astrotech has higher earnings, but lower revenue than Talis Biomedical. Astrotech is trading at a lower price-to-earnings ratio than Talis Biomedical, indicating that it is currently the more affordable of the two stocks.
Talis Biomedical has a net margin of 0.00% compared to Astrotech's net margin of -3,198.09%. Astrotech's return on equity of -40.44% beat Talis Biomedical's return on equity.
Astrotech received 119 more outperform votes than Talis Biomedical when rated by MarketBeat users. Likewise, 56.64% of users gave Astrotech an outperform vote while only 37.50% of users gave Talis Biomedical an outperform vote.
In the previous week, Astrotech's average media sentiment score of 0.18 beat Talis Biomedical's score of 0.00 indicating that Astrotech is being referred to more favorably in the media.
24.4% of Astrotech shares are held by institutional investors. Comparatively, 43.8% of Talis Biomedical shares are held by institutional investors. 14.9% of Astrotech shares are held by company insiders. Comparatively, 46.0% of Talis Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Astrotech beats Talis Biomedical on 8 of the 13 factors compared between the two stocks.
Get Talis Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLIS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talis Biomedical Competitors List
Related Companies and Tools
This page (NASDAQ:TLIS) was last updated on 2/22/2025 by MarketBeat.com Staff
